Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06510374 · ClinicalTrials.gov registry record · Phase 3
Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer
A Phase 3 study of Intermediate Risk Non-Muscle Invasive Bladder Cancer, sponsored by Ferring Pharmaceuticals.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 454
- Enrollment target
- 20
- Study locations
NCT06510374 is a Phase 3 study of Intermediate Risk Non-Muscle Invasive Bladder Cancer that is actively recruiting participants, run by Ferring Pharmaceuticals. The registered enrollment target is 454 participants. The trial reports 20 study locations across 12 states.
The verdict
NCT06510374, a Phase 3 study of Intermediate Risk Non-Muscle Invasive Bladder Cancer, is actively recruiting participants, sponsored by Ferring Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 454 participants
- Enrollment target
- 20
- Study locations
Study Summary
A phase 3b, Randomized, Controlled Trial of Nadofaragene Firadenovec vs. Observation in Participants with Intermediate Risk Non-Muscle Invasive Bladder Cancer (IR NMIBC)
Conditions Studied
Interventions
- DRUG Nadofaragene Firadenovec
Study Locations (20)
California
- Urology Associates of Central California - Fresno
- American Institute of Research - Los Angeles
- Urology Center of Southern California - Murrieta
- University of California, Irvine - Orange
- Providence Saint John's Cancer Institute - Santa Monica
Florida
- Mayo Clinic - Jacksonville
- Advanced Urology institute - Pinellas - Largo
- Sarasota Memorial Healthcare System - Sarasota
Alabama
- University of South Alabama (USA) Health System - USACM - Mobile
- Urology Associates of Mobile - Mobile
Illinois
- NextStage Clinical Research - Lisle
- Blessing Health System - Quincy
Arizona
- Mayo Clinic Arizona - Phoenix
Colorado
- Advent Health - Denver
District of Columbia
- Medstar Georgetown University Hospital - Washington D.C.
Georgia
- Emory University - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 454 participants |
| Start Date | 2024-10-01 |
| Est. Completion | 2031-06-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06510374
The ClinicalTrials.gov registry entry for NCT06510374 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 454 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ferring Pharmaceuticals, which has 83 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Intermediate Risk Non-Muscle Invasive Bladder Cancer appearing as the primary indexed condition, and to 1 intervention - of which Nadofaragene Firadenovec is the first listed.
NCT06510374 reports 20 study locations spanning 12 distinct geographic areas - top geographies include California, Florida, Alabama.
Frequently Asked Questions
What is clinical trial NCT06510374 about?
NCT06510374 is a clinical study titled "Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer". A phase 3b, Randomized, Controlled Trial of Nadofaragene Firadenovec vs. Observation in Participants with Intermediate Risk Non-Muscle Invasive Bladder Cancer (IR NMIBC)
What is the current status of trial NCT06510374?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 454 participants. The study started on 2024-10-01. Estimated completion is 2031-06-30.
What conditions does trial NCT06510374 study?
This clinical trial studies the following conditions: Intermediate Risk Non-Muscle Invasive Bladder Cancer.
What interventions are being tested in trial NCT06510374?
The interventions under investigation include: Nadofaragene Firadenovec (DRUG).
Who is sponsoring clinical trial NCT06510374?
This trial is sponsored by Ferring Pharmaceuticals, which has 83 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06510374 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.